Progyny, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Progyny reported Q3 2026 revenue of $341.3M (+8.9% YoY), gross profit of $83.7M (+15% YoY), and net income of $26.3M (+89% YoY). The company added a record 1.3 million new covered lives in its selling season with 85+ new clients and achieved near 100% client retention. Progyny raised its full-year 2026 revenue guidance to $1.365–$1.385B (5.9–7.5% growth) and Adj. EBITDA to $235–$240M. Year-to-date the company repurchased 14.3 million shares (~$231.4M in Q1–Q3 2026) across two authorization programs; ~$51M remains available.
Why this rating
Record sales season and retention, guidance raise, and strong cash-to-buyback conversion are material. At $1.9B market cap, $231M in buybacks YTD and $1.37B annual revenue represent meaningful shareholder returns and sustained growth, but organic growth (5.9–7.5%) and margin pressure offset transformational impact.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.